TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04699773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LITT
Description: This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
Study: NCT06610084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise)
Description: Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypno-breastfeeding
Description: Practices for experimental group 1 (Hypno-breastfeeding) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls.
Study: NCT05878236

Intervention type: DIAGNOSTIC_TEST
Intervention: CyTOF Analysis
Description: CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
Study: NCT06715618

Intervention type: OTHER
Intervention: FMS test
Description: Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
Study: NCT06728969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT1 Auditory startle response patterns analysis algorithm
Description: Objective measurements of attention and inhibition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT1 Auditory startle response patterns analysis algorithm
Description: Objective measurements of attention and inhibition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T.O.V.A. Continuous Performance Test
Description: Objective measurements of attention and inhibitory control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T.O.V.A. Continuous Performance Test
Description: Objective measurements of attention and inhibitory control.
Study: NCT06727864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month regimen (2HERZ/2HRE)
Description: 4-month (2HERZ/2HRE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month (2HERZ/4HRE)
Description: 2 months of HREZ followed by 4 months of HR/HRE
Study: NCT06729463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Humira
Description: Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy
Study: NCT06729619

Intervention type: DRUG
Intervention: The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
Description: Blood and cerebrospinal fluid concentrations of anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam and ceftazidime ababactam will be monitored after the drug reaches a steady state.
Study: NCT01005667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthTrack
Description: Measurement of cervical dilation and head station
Study: NCT06288568

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06005649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HY004
Description: Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells
Study: NCT04968236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: In-and-out into different directions technique to encounter sensitive spots in an MTrP region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial Dry Needling
Description: This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive stretching
Description: Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
Study: NCT04976816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator betamethasone injection
Description: The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator triamcinolone injection
Description: The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator and retrobulbar betamethasone injection
Description: In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-levator and retrobulbar triamcinolone injection
Description: In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
Study: NCT05393596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Software Intervention
Description: Virtual Reality Software Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software Intervention
Description: Virtual Reality Software Intervention
Study: NCT06395467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InTEGRA
Description: Session topics are as follows: Parent Info Session - Informational and Q\&A format; Motivation Building- Addressing AA/NA Expectancies and Experiences; AA/NA Expectancies and Treatment Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management (AA/NA and Hungry, Angry, Lonely, Tired HALT; Effective Communication (Sharing at AA/NA meetings; getting a sponsor); Depression Management; Using AA/NA for enhancing Social Support and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT
Description: Session topics are as follows: Motivation Building Session; Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management; Effective Communication; Depression Management; Enhancing the Social Support Network and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse
Study: NCT06050213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary implant overdenture
Description: maxillary overdenture retained by different number of implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary implant overdenture
Description: maxillary overdenture retained by different number of implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary implant overdenture
Description: maxillary overdenture retained by different number of implants
Study: NCT05283746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Epetraborole hydrochloride 250 mg tablets for oral administration
Study: NCT06550479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF
Description: Distal forearm AVF for hemodialysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF
Description: Distal forearm AVF for hemodialysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF
Description: Distal forearm AVF for hemodialysis.
Study: NCT01408069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIGRANE
Description: 1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARCEL
Description: 1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
Study: NCT05898516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study: NCT06369480

Intervention type: PROCEDURE
Intervention: Resection/Ablation of tumor
Description: Curative treatment

Intervention type: PROCEDURE
Intervention: Palliative chemotherapy
Description: Chemotherapeutic medications

Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapeutic medications after surgery

Intervention type: PROCEDURE
Intervention: Stereotatic radiotherapy
Description: Radiotherapy

Intervention type: PROCEDURE
Intervention: Best supportive care
Description: Symptomatic treatment, non-curative treatment
Study: NCT04487548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote smoking cessation bundle
Description: The bundle is a remote version of what has previously been described in prior literature, which includes:~1. A brief (\<5 minutes) advice~2. Preoperative smoking cessation video prepared by QuitNow~3. Patients will be provided brochures on smoking cessation~4. A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~5. All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year.
Study: NCT05987800

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Titration procedure
Description: The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electrical impedance tomography
Description: This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung and diaphragm ultrasound
Description: Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure.
Study: NCT06330415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SME tool
Description: The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
Study: NCT05233735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel
Description: Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion

Intervention type: OTHER
Group type: OTHER
Intervention: Topical treatment
Description: betamethasone ointment treatment once per day
Study: NCT05322096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-706
Description: Capsules~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules~Oral administration
Study: NCT06000644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined group
Description: The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive group
Description: The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic group
Description: The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill group
Description: The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
Study: NCT04623710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Study: NCT06140186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Timolol
Description: Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate
Description: Betamethasone valerate 0.1% cream application twice daily
Study: NCT04809116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
Study: NCT05095519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
Study: NCT05339958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrafol® Men Hair Growth Nutraceutical
Description: Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: The placebo capsules contain no active ingredients.
Study: NCT05143424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine sulfate 30 mg tablets as a single dose twice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine sulfate 30 mg tablets as a single dose twice
Study: NCT06326736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered 6 weeks post-tumor resection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SJ-Neo006
Description: SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Abraxane
Description: Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
Study: NCT06261723

Intervention type: PROCEDURE
Intervention: non-chirurgical periodontal treatment
Description: The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.

Intervention type: PROCEDURE
Intervention: non-chirurgical periodontal treatment
Description: The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
Study: NCT05691543

Intervention type: PROCEDURE
Intervention: sacrospinous fixation Using Posterior Vaginal wall flap
Description: * Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,
Study: NCT04862338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide (NMN-C)
Description: Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
Study: NCT04582656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted microwave ablation
Description: Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
Study: NCT06454786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation Method
Description: Management of cardiogenic shock scenario on an advanced simulation mannequin